<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd"><PubmedArticleSet><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35928647</PMID><DateRevised><Year>2022</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2229-3485</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Season>Jul-Sep</Season></PubDate></JournalIssue><Title>Perspectives in clinical research</Title><ISOAbbreviation>Perspect Clin Res</ISOAbbreviation></Journal><ArticleTitle>Effects of antihypertensive agents on the quality of life in diabetic hypertensive patients: A prospective study.</ArticleTitle><Pagination><StartPage>137</StartPage><EndPage>144</EndPage><MedlinePgn>137-144</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/picr.PICR_15_20</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Diabetes mellitus is a chronic noncommunicable disease, and hypertension (HT) is the most common comorbidity which affects their quality of life (QoL).</AbstractText><AbstractText Label="AIM" NlmCategory="UNASSIGNED">The aim of the study was to assess the effects of antihypertensive agents (viz., amlodipine, ramipril, telmisartan, and ramipril with telmisartan) on the blood pressure (BP) and QoL.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="UNASSIGNED">It was an open-labeled prospective intention-to-treat study done in diabetic hypertensive patients (<i>CTRI</i>/2016/10<i>/007340</i>). Patients were randomly assigned antihypertensive agents, namely, amlodipine, ramipril, telmisartan, and a combination of ramipril with telmisartan (RT) in four groups. They were evaluated for BP, blood sugar level, and QoL at baseline and 24<sup>th</sup> week.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">After 24 weeks of therapy, systolic BP (SBP) and diastolic BP (DBP) were significantly reduced in all groups. In amlodipine, there was a mean percentage fall of SBP by 15.85% (confidence interval [CI]: 21.38-28.13) and DBP by 11.22% (CI: 8.41-12.70); in ramipril - 14.4% (CI: 18.61-25.15) and 12.4% (CI 8.88-13.99); telmisartan - 18.4% (CI: 24.89-10.79) and 14.6% (CI 10.79-16.24); and in RT group, SBP 17.7% (CI: 23.38-29.18) and DBP 12.4% (CI: 9.05-13.02). QoL score increased by 30.56% (CI: 14.30-10.90), 30.94% (CI: 14.21-10.68), 28.07% (CI: 14.89-11.20), and 28.84% (CI: 15.49-11.77), in respective groups (<i>P</i> &lt; 0.0001, each). However, they were nonsignificant between the study groups (<i>P</i> &gt; 0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Amlodipine, ramipril, telmisartan, and a combination of RT are equally effective to improve BP and QoL among diabetic hypertensive patients. However, amlodipine and telmisartan lacked in dry cough and more tolerable than the ramipril and RT therapy. Henceforth, amlodipine and telmisartan are better choice to control HT among DM patients.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2021 Perspectives in Clinical Research.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhardwaj</LastName><ForeName>Raj Kumar</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, GGS Medical College and Hospital, Baba Farid University of Health Sciences, Faridkot, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kazal</LastName><ForeName>H L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Department of Medicine, PIMS, Jalandhar, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohli</LastName><ForeName>Kamlesh</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, GGS Medical College and Hospital, Baba Farid University of Health Sciences, Faridkot, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raj</LastName><ForeName>Rajnish</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Government Medical College, Patiala, Punjab, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bansal</LastName><ForeName>Nagma</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, GGS Medical College and Hospital, Baba Farid University of Health Sciences, Faridkot, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Baltej</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Community Medicine, GGS Medical College and Hospital, Baba Farid University of Health Sciences, Faridkot, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arora</LastName><ForeName>Hobinder</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Community Medicine, GGS Medical College and Hospital, Baba Farid University of Health Sciences, Faridkot, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Perspect Clin Res</MedlineTA><NlmUniqueID>101551517</NlmUniqueID><ISSNLinking>2229-3485</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amlodipine</Keyword><Keyword MajorTopicYN="N">Quality of Life Instrument in Diabetes Patients</Keyword><Keyword MajorTopicYN="N">blood pressure</Keyword><Keyword MajorTopicYN="N">ramipril</Keyword><Keyword MajorTopicYN="N">telmisartan</Keyword></KeywordList><CoiStatement>There are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>5</Day><Hour>2</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35928647</ArticleId><ArticleId IdType="pmc">PMC9345252</ArticleId><ArticleId IdType="doi">10.4103/picr.PICR_15_20</ArticleId><ArticleId IdType="pii">PCR-13-137</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>International Diabetes Federation. IDF DIABETES ATLAS Sixth edition (2013). Available via DIALOG.  [Last accessed on 2015 Oct 19].  Available from: https://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf .</Citation></Reference><Reference><Citation>World Health Organization, WHOQOL: Measuring Quality of Life. Available via DIALOG.  [Last accessed on 2020 Jan 10].  Available from: https://www.who.int/healthinfo/survey/whoqol-qualityoflife/en/index1.html .</Citation></Reference><Reference><Citation>Prajapati VB, Blake R, Acharya LD, Seshadri S. Assessment of quality of life in type II diabetic patients using the modified diabetes quality of life (MDQoL)-17 questionnaire. Braz J Pharm Sci. 2017;53:e17144&#x2013;8.</Citation></Reference><Reference><Citation>Daivashiromani V, Kuna A, Devi SS, Kumari PA, Sowmya M. Effect of selected demographic characters on health related quality of life (HRQOL) in Type 2 diabetic subjects of Hyderabad and Rangareddy districts of Telangana State. The J Res PJTSAU. 2017;45:104&#x2013;12.</Citation></Reference><Reference><Citation>Nagpal J, Kumar A, Kakar S, Bhartia A. The development of &#x201c;quality of life instrument for Indian diabetes patients (QOLID): A validation and reliability study in middle and higher income groups. J Assoc Physicians India. 2010;58:295&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">21117348</ArticleId></ArticleIdList></Reference><Reference><Citation>Standard Treatment Guidelines.Hypertension Screening, Diagnosis, Assessment and Management of Primary Hypertension in Adults in India-Quick Reference Guide (2016). Ministry of Health and Family Welfare, Government of India 2016. Available via DIALOG.  [Last accessed on 2018 Dec 11].  Available from: http://clinicalestablishments.gov.in/WriteReadData/6591.pdf.18 .</Citation></Reference><Reference><Citation>Zaman ZA, Kumari V. Comparison of the effects of amlodipine and cilnidipine on blood pressure, heart rate, proteinuria and lipid profile in hypertensive patients. Int J Basic Clin Pharmacol. 2013;2:160&#x2013;4.</Citation></Reference><Reference><Citation>Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA. 2001;285:2719&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">11386927</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">18378520</ArticleId></ArticleIdList></Reference><Reference><Citation>Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, et al. Safety and efficacy of low blood pressures among patients with diabetes: Subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) J Am Coll Cardiol. 2012;59:74&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">22192672</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadge P, Gadge R, Paralkar N, Jain P, Tanna V. Effect of telmisartan on blood pressure in patients of type 2 diabetes with or without complications. Perspect Clin Res. 2018;9:155&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6176690</ArticleId><ArticleId IdType="pubmed">30319944</ArticleId></ArticleIdList></Reference><Reference><Citation>Delles C, Raff U, Mimran A, Fauvel JP, Ruilope LM, Schmieder RE. Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes. Am J Hypertens. 2008;21:1330&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18989258</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto S, Yano Y, Maki K, Sawada K. Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res. 2006;29:567&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">17137211</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet. 2003;361:117&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">12531578</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavi A, Walvekar P, Mallapur M. Assessment of health related quality of life of elderly diabetic patients attending urban primary health care facility-a cross sectional study. Int J Community Med Public Health. 2017;3:2258&#x2013;63.</Citation></Reference><Reference><Citation>Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, et al. Systematic review: Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148:16&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">17984484</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaturvedi R, Desai C, Patel P, Shah A, Dikshit RK. An evaluation of the impact of antidiabetic medication on treatment satisfaction and quality of life in patients of diabetes mellitus. Perspect Clin Res. 2018;9:15&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5799947</ArticleId><ArticleId IdType="pubmed">29430413</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28045910</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis.</ArticleTitle><Pagination><StartPage>e0168582</StartPage><MedlinePgn>e0168582</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0168582</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0168582</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Antihypertensive treatment mitigates the progression of chronic kidney disease. Here, we comparatively assessed the effects of antihypertensive agents in normotensive and hypertensive diabetic patients with microalbuminuric kidney disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were systematically searched for randomized controlled trials (RCTs) comparing oral antihypertensive agents in adult diabetic patients with microalbuminuria. The primary efficacy outcome was reduction in albuminuria, and the primary safety outcomes were dry cough, presyncope, and edema. Random-effects pairwise and Bayesian network meta-analyses were performed to produce outcome estimates for all RCTs, only hypertensive RCTs, or only normotensive RCTs. Surface under the cumulative ranking (SUCRA) probability rankings were calculated for all outcomes. Sensitivity analyses on type 2 diabetes status, age, or follow-up duration were also performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 38 RCTs were included in the meta-analyses. The angiotensin-converting enzyme inhibitor-calcium channel blocker (ACEI-CCB) combination therapy of captopril+diltiazem was most efficacious in reducing albuminuria irrespective of blood pressure status. However, the ACEI-angiotensin receptor blocker (ACEI-ARB) combination therapy of trandolapril+candesartan was the most efficacious in reducing albuminuria for normotensive patients, while the ACEI-CCB combination therapy of fosinopril+amlodipine was the most efficacious in reducing albuminuria for hypertensive patients. The foregoing combination therapies displayed inferior safety profiles relative to ACEI monotherapy with respect to dry cough, presyncope, and edema. With respect to type 2 diabetic patients with microalbuminuria, the Chinese herbal medicine Tangshen formula followed by the ACEI ramipril were the most efficacious in reducing albuminuria.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Trandolapril+candesartan appears to be the most efficacious intervention for reducing albuminuria for normotensive patients, while fosinopril+amlodipine appears to be the most efficacious intervention for reducing albuminuria for hypertensive patients. For practitioners opting for monotherapy, our SUCRA analysis supports the use of trandolapril and fosinopril in normotensive and hypertensive adult diabetic patients with microalbuminuria, respectively.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Rongzhong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Yuxing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, the Ninth People's Hospital of Chongqing, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Xiaoxia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melgiri</LastName><ForeName>Narayan Dhruvaraj</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Impactys Foundation for Biomedical Research, San Diego, CA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Ultrasound Imaging, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xingsheng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Gerontology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013777">Tetrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>1T0N3G9CRC</RegistryNumber><NameOfSubstance UI="C052035">trandolapril</NameOfSubstance></Chemical><Chemical><RegistryNumber>R43D2573WO</RegistryNumber><NameOfSubstance UI="D017328">Fosinopril</NameOfSubstance></Chemical><Chemical><RegistryNumber>S8Q36MD2XX</RegistryNumber><NameOfSubstance UI="C081643">candesartan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000419" MajorTopicYN="N">Albuminuria</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001713" MajorTopicYN="N">Biphenyl Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017328" MajorTopicYN="N">Fosinopril</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007674" MajorTopicYN="N">Kidney Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061214" MajorTopicYN="N">Patient Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013777" MajorTopicYN="N">Tetrazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28045910</ArticleId><ArticleId IdType="pmc">PMC5207630</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0168582</ArticleId><ArticleId IdType="pii">PONE-D-16-20167</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guariguata L, Whiting D, Hambleton I, Beagley J, Linnenkamp U, Shaw J. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes research and clinical practice. 2014;103(2):137&#x2013;49. 10.1016/j.diabres.2013.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2013.11.002</ArticleId><ArticleId IdType="pubmed">24630390</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong C-S, Chung K-M, Huang P-C, Wang J-J, Yang C-M, Chu C-C, et al. Epidemiology and Mortality of Liver Abscess in End-Stage Renal Disease Dialysis Patients: Taiwan National Cohort Study. PloS one. 2014;9(2):e88078 10.1371/journal.pone.0088078</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0088078</ArticleId><ArticleId IdType="pmc">PMC3925100</ArticleId><ArticleId IdType="pubmed">24551077</ArticleId></ArticleIdList></Reference><Reference><Citation>Molitch ME, Adler AI, Flyvbjerg A, Nelson RG, So W-Y, Wanner C, et al. Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney international. 2015;87(1):20&#x2013;30. 10.1038/ki.2014.128</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2014.128</ArticleId><ArticleId IdType="pmc">PMC4214898</ArticleId><ArticleId IdType="pubmed">24786708</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. American journal of kidney diseases. 2000;36(3):646&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">10977801</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarafidis PA, Ruilope LM. Aggressive blood pressure reduction and renin&#x2013;angiotensin system blockade in chronic kidney disease: time for re-evaluation&amp;quest. Kidney international. 2014;85(3):536&#x2013;46. 10.1038/ki.2013.355</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2013.355</ArticleId><ArticleId IdType="pubmed">24048382</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. The Lancet. 2015;385(9982):2047&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">26009228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakris GL, Molitch M. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014;37(3):867&#x2013;75. 10.2337/dc13-1870</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc13-1870</ArticleId><ArticleId IdType="pubmed">24558077</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA consensus conference. American Journal of Kidney Diseases. 2014;64(4):510&#x2013;33. 10.1053/j.ajkd.2014.08.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2014.08.001</ArticleId><ArticleId IdType="pubmed">25257325</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of internal medicine. 2009;151(4):264&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19622511</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value in Health. 2011;14(4):417&#x2013;28. 10.1016/j.jval.2011.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2011.04.002</ArticleId><ArticleId IdType="pubmed">21669366</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value in Health. 2011;14(4):429&#x2013;37. 10.1016/j.jval.2011.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2011.01.011</ArticleId><ArticleId IdType="pubmed">21669367</ArticleId></ArticleIdList></Reference><Reference><Citation>MacIsaac RJ, Jerums G. Diabetic kidney disease with and without albuminuria. Current opinion in nephrology and hypertension. 2011;20(3):246&#x2013;57. 10.1097/MNH.0b013e3283456546</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MNH.0b013e3283456546</ArticleId><ArticleId IdType="pubmed">21422923</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. The American journal of medicine. 2007;120(9):783&#x2013;90. 10.1016/j.amjmed.2007.04.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2007.04.023</ArticleId><ArticleId IdType="pubmed">17765048</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa TA, McGuire H, Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. Bmj. 2002;325(7371):991</Citation><ArticleIdList><ArticleId IdType="pmc">PMC131022</ArticleId><ArticleId IdType="pubmed">12411354</ArticleId></ArticleIdList></Reference><Reference><Citation>White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1998;18(3):588&#x2013;99.</Citation></Reference><Reference><Citation>Israili Z. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. Journal of Human Hypertension. 2000;14:S73&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">10854085</ArticleId></ArticleIdList></Reference><Reference><Citation>Leenen FH, Fourney A. Comparison of the effects of amlodipine and diltiazem on 24-hour blood pressure, plasma catecholamines, and left ventricular mass. The American journal of cardiology. 1996;78(2):203&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8712143</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AD. How do thiazide and thiazide-like diuretics lower blood pressure? Journal of Renin-angiotensin-aldosterone system. 2004;5(4):155&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15803433</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. New England Journal of Medicine. 2013;369(20):1892&#x2013;903. 10.1056/NEJMoa1303154</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303154</ArticleId><ArticleId IdType="pubmed">24206457</ArticleId></ArticleIdList></Reference><Reference><Citation>Parving H-H, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. New England Journal of Medicine. 2012;367(23):2204&#x2013;13. 10.1056/NEJMoa1208799</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1208799</ArticleId><ArticleId IdType="pubmed">23121378</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. The Lancet. 2008;372(9638):547&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">18707986</ArticleId></ArticleIdList></Reference><Reference><Citation>James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Jama. 2014;311(5):507&#x2013;20. 10.1001/jama.2013.284427</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.284427</ArticleId><ArticleId IdType="pubmed">24352797</ArticleId></ArticleIdList></Reference><Reference><Citation>Qaseem A, Centor R, Dunn A, Baker DW, Centor RM, Cross JT, et al. Screening, Monitoring, and Management of Chronic Kidney Disease: Review of the Performance Measures by the Performance Measurement Committee of the American College of Physicians. 2014.</Citation></Reference><Reference><Citation>Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. American Journal of Kidney Diseases. 2014;63(5):713&#x2013;35. 10.1053/j.ajkd.2014.01.416</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2014.01.416</ArticleId><ArticleId IdType="pubmed">24647050</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Zhang B, Lu X, Yan M, Wen Y, Zhao T, et al. Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease. BMC Complementary and Alternative Medicine. 2016;16(1):246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4962377</ArticleId><ArticleId IdType="pubmed">27460780</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Chen Y, Liu J, Hong J, Deng Y, Yang F, et al. Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial. PloS one. 2015;10(5):e0126027 10.1371/journal.pone.0126027</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0126027</ArticleId><ArticleId IdType="pmc">PMC4418676</ArticleId><ArticleId IdType="pubmed">25938778</ArticleId></ArticleIdList></Reference><Reference><Citation>Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J. Reno-protective effects of renin&#x2013;angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia. 2012;55(3):566&#x2013;78. 10.1007/s00125-011-2398-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-011-2398-8</ArticleId><ArticleId IdType="pmc">PMC3268972</ArticleId><ArticleId IdType="pubmed">22189484</ArticleId></ArticleIdList></Reference><Reference><Citation>Estacio RO, Coll JR, Tran ZV, Schrier RW. Effect of Intensive Blood Pressure Control With Valsartan on Urinary Albumin Excretion in Normotensive Patients With Type 2 Diabetes*. American journal of hypertension. 2006;19(12):1241&#x2013;8. 10.1016/j.amjhyper.2006.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjhyper.2006.05.011</ArticleId><ArticleId IdType="pubmed">17161769</ArticleId></ArticleIdList></Reference><Reference><Citation>Atmaca A, Gedik O. Effects of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and their combination on microalbuminuria in normotensive patients with type 2 diabetes. Advances in therapy. 2006;23(4):615&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">17050503</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojestig M, Karlberg BE, Lindstr&#xf6;m T, Nystrom FH. Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes. Diabetes Care. 2001;24(5):919&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">11347755</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Bmj. 2000;321(7274):1440&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27545</ArticleId><ArticleId IdType="pubmed">11110735</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima M, Ohashi M, Dohi Y, Kimura G. Titration of telmisartan, but not addition of amlodipine, reduces urine albumin in diabetic patients treated with telmisartan&#x2013;diuretic. Journal of hypertension. 2013;31(1):186&#x2013;91. 10.1097/HJH.0b013e32835a2724</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0b013e32835a2724</ArticleId><ArticleId IdType="pubmed">23047595</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaturvedi N, Group ES. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The Lancet. 1997;349(9068):1787&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">9269212</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogari R, Zoppi A, Malamani G, Lusardi P, Destro M, Corradi L. Effects of amlodipine vs enalapril on microalbuminuria in hypertensive patients with type II diabetes. Clinical drug investigation. 1997;13(1):42&#x2013;9.</Citation></Reference><Reference><Citation>Fogari R, Zoppi A, Corradi L, Poletti L, Pasotti M, Fogari E, et al. Long-term effects of amlodipine versus fosinopril on microalbuminuria in elderly hypertensive patients with type 2 diabetes mellitus. Current therapeutic research. 2000;61(3):163&#x2013;73.</Citation></Reference><Reference><Citation>Fogari R, Preti P, Zoppi A, Rinaldi A, Corradi L, Pasotti C, et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. American journal of hypertension. 2002;15(12):1042&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12460699</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, et al. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. European journal of clinical pharmacology. 2005;61(7):483&#x2013;90. 10.1007/s00228-005-0961-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-005-0961-2</ArticleId><ArticleId IdType="pubmed">16021438</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogari R, Corradi L, Zoppi A, Lazzari P, Mugellini A, Preti P, et al. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. American journal of hypertension. 2007;20(10):1092&#x2013;6. 10.1016/j.amjhyper.2007.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjhyper.2007.05.012</ArticleId><ArticleId IdType="pubmed">17903693</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogari R, Derosa G, Zoppi A, Lazzari P, D'Angelo A, Mugellini A. Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria. Expert opinion on pharmacotherapy. 2014;15(4):453&#x2013;9. 10.1517/14656566.2014.874415</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.2014.874415</ArticleId><ArticleId IdType="pubmed">24410484</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogari R, Mugellini A, Zoppi A, Gualtierotti R, Lazzari P, Derosa G, et al. Effect of imidapril versus ramipril on urinary albumin excretion in hypertensive patients with type 2 diabetes and microalbuminuria. Expert opinion on pharmacotherapy. 2013;14(18):2463&#x2013;73. 10.1517/14656566.2013.848195</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.2013.848195</ArticleId><ArticleId IdType="pubmed">24195786</ArticleId></ArticleIdList></Reference><Reference><Citation>Katayama S, Kikkawa R, Isogai S, Sasaki N, Matsuura N, Tajima N, et al. Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diabetes research and clinical practice. 2002;55(2):113&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">11796177</ArticleId></ArticleIdList></Reference><Reference><Citation>Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. American journal of kidney diseases. 2001;37(5):890&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11325669</ArticleId></ArticleIdList></Reference><Reference><Citation>Josefsberg Z, Ross SA, Lev-Ran A, Hwang DL. Effects of enalapril and nitrendipine on the excretion of epidermal growth factor and albumin in hypertensive NIDDM patients. Diabetes care. 1995;18(5):690&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">8586009</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohlmann O Jr, Roca-Cusachs A, Laurent S, Schmieder RE, Wenzel RR, Fogari R. Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. Advances in therapy. 2009;26(3):313&#x2013;24. 10.1007/s12325-009-0015-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-009-0015-8</ArticleId><ArticleId IdType="pubmed">19330493</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacourci&#xe8;re Y, B&#xe9;langer A, Godin C, Hall&#xe9; J-P, Ross S, Wright N, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney international. 2000;58(2):762&#x2013;9. 10.1046/j.1523-1755.2000.00224.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1523-1755.2000.00224.x</ArticleId><ArticleId IdType="pubmed">10916100</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Chen Y, Liu J, Hong J, Deng Y, Yang F, et al. Efficacy and Safety of Tangshen Formula on Patients with Type 2 Diabetic Kidney Disease: A Multicenter Double-Blinded Randomized Placebo-Controlled Trial. 2015. 10.1371/journal.pone.0126027</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0126027</ArticleId><ArticleId IdType="pmc">PMC4418676</ArticleId><ArticleId IdType="pubmed">25938778</ArticleId></ArticleIdList></Reference><Reference><Citation>Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus a blood pressure&#x2013;independent effect. Circulation. 2002;106(6):672&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12163426</ArticleId></ArticleIdList></Reference><Reference><Citation>Muirhead N, Feagan BF, Mahon J, Lewanczuk RZ, Rodger NW, Botteri F, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Current therapeutic research. 1999;60(12):650&#x2013;60.</Citation></Reference><Reference><Citation>Group MDNS. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ. 1991;302(6770):210&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1669057</ArticleId><ArticleId IdType="pubmed">1998761</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T, Ushiyama C, Osada S, Takahashi Y, Shimada N, Ebihara I, et al. Combination therapy of trandolapril and candesartan cilexetil reduces microalbuminuria and urinary endothelin-1 excretion in patients with type 2 diabetes. Clinical and experimental nephrology. 2002;6(3):135&#x2013;9. 10.1007/s101570200023</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s101570200023</ArticleId><ArticleId IdType="pubmed">24989952</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Maraver M, Carrera MJ, Mical&#xf3; T, Sahun M, Vinzia C, Soler J, et al. Renoprotective effect of diltiazem in hypertensive type 2 diabetic patients with persistent microalbuminuria despite ACE inhibitor treatment. Diabetes research and clinical practice. 2005;70(1):13&#x2013;9. 10.1016/j.diabres.2005.02.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2005.02.019</ArticleId><ArticleId IdType="pubmed">16126118</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulsen P, Ebbeh&#xf8;j E, Mogensen CE. Lisinopril reduces albuminuria during exercise in low grade microalbuminuric type 1 diabetic patients: a double blind randomized study. Journal of internal medicine. 2001;249(5):433&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">11350567</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes preterax in albuminuria regression: PREMIER. Hypertension. 2003;41(5):1063&#x2013;71. 10.1161/01.HYP.0000064943.51878.58</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.0000064943.51878.58</ArticleId><ArticleId IdType="pubmed">12654706</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano T, Kawamura T, Matsumae H, Sasaki H, Nakayama M, Hara T, et al. Effects of long-term enalapril treatment on persistent microalbuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care. 1994;17(5):420&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8062609</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato A, Tabata M, Hayashi K, Saruta T. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy. Journal of Clinical and Experimental Nephrology. 2003;7(3):215&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">14586718</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnack C, Capek M, Banyai M, Kautzky-Willer A, Prager R, Schernthaner G. Long-term treatment with nifedipine reduces urinary albumin excretion and glomerular filtration rate in normotensive type 1 diabetic patients with microalbuminuria. Acta diabetologica. 1994;31(1):14&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8043891</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengul AM, Altuntas Y, K&#xfc;rkl&#xfc; A, Ayd&#x131;n L. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes research and clinical practice. 2006;71(2):210&#x2013;9. 10.1016/j.diabres.2005.06.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2005.06.010</ArticleId><ArticleId IdType="pubmed">16112244</ArticleId></ArticleIdList></Reference><Reference><Citation>SHIGIHARA T, SATO A, HAYASHI K, SARUTA T. Effect of Combination Therapy of Angiotensin-Converting Enzyme Inhibitor plus Calcium Channel Blocker on Urinary Albumin Excretion in Hypertensive Microalubuminuric Patients with Type II Diabetes. Hypertension Research. 2000;23(3):219&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">10821130</ArticleId></ArticleIdList></Reference><Reference><Citation>Takebayashi K, Matsumoto S, Aso Y, Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. The Journal of Clinical Endocrinology &amp; Metabolism. 2006;91(6):2214&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16569732</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan KC, Chow WS, Ai VH, Lam KS. Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria. Diabetes/metabolism research and reviews. 2002;18(1):71&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11921421</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xfc;t&#xfc;nc&#xfc; N, G&#xfc;rlek A, Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta diabetologica. 2001;38(4):157&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">11855793</ArticleId></ArticleIdList></Reference><Reference><Citation>Weil EJ, Fufaa G, Jones LI, Lovato T, Lemley KV, Hanson RL, et al. Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes. 2013;62(9):3224&#x2013;31. 10.2337/db12-1512</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db12-1512</ArticleId><ArticleId IdType="pmc">PMC3749332</ArticleId><ArticleId IdType="pubmed">23545707</ArticleId></ArticleIdList></Reference><Reference><Citation>Viberti G, Mogensen CE, Groop LC, Pauls JF, Boner G, van Dyk D, et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. Jama. 1994;271(4):275&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8295285</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandbergen AA, Baggen MG, Lamberts SW, Bootsma AH, de Zeeuw D, Rob JT. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial. Annals of Internal Medicine. 2003;139(2):90&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859158</ArticleId></ArticleIdList></Reference><Reference><Citation>Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC medical research methodology. 2005;5(1):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1097734</ArticleId><ArticleId IdType="pubmed">15840177</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23027453</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0171-2004</ISSN><JournalIssue CitedMedium="Print"><Issue>214</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>Handbook of experimental pharmacology</Title><ISOAbbreviation>Handb Exp Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Sex and gender differences in cardiovascular drug therapy.</ArticleTitle><Pagination><StartPage>211</StartPage><EndPage>236</EndPage><MedlinePgn>211-36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-642-30726-3_11</ELocationID><Abstract><AbstractText>This chapter outlines sex differences in pharmacokinetics and pharmacodynamics of the most frequently used drugs in cardiovascular diseases, e.g., coronary artery disease, hypertension, heart failure. Retrospective analysis of previously published drug trials revealed marked sex differences in efficacy and adverse effects in a number of cardiovascular drugs. This includes a higher mortality among women taking digoxin for heart failure, more torsade de pointes arrhythmia in QT prolonging drugs and more cough with ACE inhibitors. Trends towards a greater benefit for women and/or female animals have been observed in some studies for endothelin receptor antagonists, the calcium channel blocker amlodipine, the ACE-inhibitor ramipril and the aldosterone antagonist eplerenone. However, reproduction of these results in independent studies and solid statistical evidence is still lacking. Some drugs require a particularly careful dose adaptation in women: the beta-blocker metoprolol, the calcium channel blocker verapamil, loop-, and thiazide diuretics. In conclusion, sex differences in pharmacokinetics and pharmacodynamics have to be taken into account for cardiovascular drug therapy in women.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seeland</LastName><ForeName>Ute</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Institute of Gender in Medicine, Universitaetsmedizin Berlin Charit&#xe9;, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regitz-Zagrosek</LastName><ForeName>Vera</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Handb Exp Pharmacol</MedlineTA><NlmUniqueID>7902231</NlmUniqueID><ISSNLinking>0171-2004</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065128">Endothelin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012739">Gonadal Steroid Hormones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000319" MajorTopicYN="N">Adrenergic beta-Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065128" MajorTopicYN="N">Endothelin Receptor Antagonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012739" MajorTopicYN="N">Gonadal Steroid Hormones</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="Y">Sex Characteristics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23027453</ArticleId><ArticleId IdType="doi">10.1007/978-3-642-30726-3_11</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20033075</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5527</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>9</Issue><PubDate><Year>2010</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of human hypertension</Title><ISOAbbreviation>J Hum Hypertens</ISOAbbreviation></Journal><ArticleTitle>Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial.</ArticleTitle><Pagination><StartPage>600</StartPage><EndPage>608</EndPage><MedlinePgn>600-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/jhh.2009.107</ELocationID><Abstract><AbstractText>Efficacy and safety of the direct renin inhibitor aliskiren was compared with ramipril for treatment of essential systolic hypertension in elderly patients. A 36-week, randomized, double-blind, parallel-group, active-controlled, optional-titration study was performed in 901 patients (aliskiren, n=457; ramipril, n=444) &gt; or =65 years of age with systolic blood pressure (SBP) &gt; or =140 mm Hg. Aliskiren 150-300 mg per day or ramipril 5-10 mg per day for was administered for 12 weeks with optional add-on therapy of hydrochlorothiazide (12.5-25 mg per day) at week 12 and amlodipine (5-10 mg per day) at week 22. The primary end point was non-inferiority of aliskiren vs ramipril monotherapy for change from baseline in mean sitting SBP (msSBP) at week 12. Decreases from baseline msSBP and mean sitting diastolic BP with aliskiren monotherapy (-14.0 and -5.1 mm Hg, respectively) were non-inferior (P&lt;0.001 for both values) and superior to ramipril monotherapy (-11.6, -3.6 mm Hg; P=0.02, P&lt;0.01, respectively). More patients achieved BP control with aliskiren (42%) than ramipril (33%; P&lt;0.01). At week 36, fewer patients receiving aliskiren-based therapy required add-on treatment with hydrochlorothiazide or amlodipine (P=0.01 and 0.048, respectively). Tolerability was similar, but more patients receiving ramipril reported cough (P&lt;0.001). In elderly patients with systolic hypertension, aliskiren proved to be more effective and better overall anti-hypertensive therapy compared to ramipril.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duprez</LastName><ForeName>D A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, Medical School, University of Minnesota, Minneapolis, MN 55544, USA. dupre007@umn.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munger</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Botha</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Keefe</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Charney</LastName><ForeName>A N</ForeName><Initials>AN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>12</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Hum Hypertens</MedlineTA><NlmUniqueID>8811625</NlmUniqueID><ISSNLinking>0950-9240</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000577">Amides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005650">Fumarates</NameOfSubstance></Chemical><Chemical><RegistryNumber>502FWN4Q32</RegistryNumber><NameOfSubstance UI="C446481">aliskiren</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.15</RegistryNumber><NameOfSubstance UI="D012083">Renin</NameOfSubstance></Chemical><Chemical><RegistryNumber>L35JN3I7SJ</RegistryNumber><NameOfSubstance UI="D017257">Ramipril</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000577" MajorTopicYN="N">Amides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005650" MajorTopicYN="N">Fumarates</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017257" MajorTopicYN="N">Ramipril</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012083" MajorTopicYN="N">Renin</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20033075</ArticleId><ArticleId IdType="doi">10.1038/jhh.2009.107</ArticleId><ArticleId IdType="pii">jhh2009107</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18840367</PMID><DateCompleted><Year>2009</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0149-2918</ISSN><JournalIssue CitedMedium="Print"><Volume>30</Volume><Issue>9</Issue><PubDate><Year>2008</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Clinical therapeutics</Title><ISOAbbreviation>Clin Ther</ISOAbbreviation></Journal><ArticleTitle>An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.</ArticleTitle><Pagination><StartPage>1618</StartPage><EndPage>1628</EndPage><MedlinePgn>1618-28</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinthera.2008.09.008</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A combination of antihypertensive agents of different drug classes in a fixed-dose combination (FDC) may offer advantages in terms of efficacy, tolerability, and treatment compliance. Combination of a calcium channel blocker with an angiotensin-converting enzyme inhibitor may act synergistically to reduce blood pressure (BP).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to compare the efficacy and tolerability of an amlodipine/ramipril FDC with those of amlodipine monotherapy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This 18-week, prospective, randomized, double-blind study was conducted at 8 centers across Brazil. Patients with stage 1 or 2 essential hypertension were enrolled. After a 2-week placebo run-in phase, patients received amlodipine/ramipril 2.5/2.5 mg or amlodipine 2.5 mg, after which the doses were titrated, based on BP, to 5/5 then 10/10 mg (amlodipine/ramipril) and 5 then 10 mg (amlodipine). The primary end point was BP measured in the intent-to-treat (ITT) population. Hematology and serum biochemistry were assessed at baseline and study end. Tolerability was assessed using patient interview, laboratory analysis, and physical examination, including measurement of ankle circumference to assess peripheral edema.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 222 patients completed the study (age range, 40-79 years; FDC group, 117 patients [mean dose, 7.60/7.60 mg]; monotherapy, 105 patients [mean dose, 7.97 mg]). The mean (SD) changes in systolic BP (SBP) and diastolic BP (DBP), as measured using 24-hour ambulatory blood pressure monitoring (ABPM) and in the physician's office, were significantly greater with combination therapy than monotherapy, with the exception of office DBP (ABPM, -20.76 [1.25] vs -15.80 [1.18] mm Hg and -11.71 [0.78] vs -8.61 [0.74] mm Hg, respectively [both, P = 0.004]; office, -27.51 [1.40] vs -22.84 [1.33] mm Hg [P = 0.012] and -16.41 [0.79] vs -14.64 [0.75] mm Hg [P = NS], respectively). In the ITT analysis, the mean changes in ambulatory, but not office-based, BP were statistically significant (ABPM: SBP, -20.21 [1.14] vs -15.31 [1.12] mm Hg and DBP, -11.61 [0.72] vs -8.42 [0.70] mm Hg, respectively [both, P = 0.002]; office: SBP, -26.60 [1.34] vs -22.97 [1.30] mm Hg and DBP, -16.48 [0.78] vs -14.48 [0.75] mm Hg [both, P = NS]). Twenty-nine patients (22.1%) treated with combination therapy and 41 patients (30.6%) treated with monotherapy experienced &gt; or =1 adverse event considered possibly related to study drug. The combination-therapy group had lower prevalence of edema (7.6% vs 18.7%; P = 0.011) and a similar prevalence of dry cough (3.8% vs 0.8%; P = NS). No clinically significant changes in laboratory values were found in either group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this population of patients with essential hypertension, the amlodipine/ramipril FDC was associated with significantly reduced ambulatory and office-measured BP compared with amlodipine monotherapy, with the exception of office DBP. Both treatments were well tolerated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miranda</LastName><ForeName>Roberto Dischinger</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Federal University of S&#x103;o Paulo, S&#x103;o Paulo, Brazil. roberto.miranda@uol.com.br</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mion</LastName><ForeName>D&#xe9;cio</ForeName><Initials>D</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Rocha</LastName><ForeName>Jo&#x103;o Carlos</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Kohlmann</LastName><ForeName>Oswaldo</ForeName><Initials>O</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Gomes</LastName><ForeName>Marco Antonio Mota</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Saraiva</LastName><ForeName>Jos&#xe9; Francisco Kerr</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Amodeo</LastName><ForeName>Celso</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Filho</LastName><ForeName>Br&#xe1;ulio Luna</ForeName><Initials>BL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Ther</MedlineTA><NlmUniqueID>7706726</NlmUniqueID><ISSNLinking>0149-2918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>1J444QC288</RegistryNumber><NameOfSubstance UI="D017311">Amlodipine</NameOfSubstance></Chemical><Chemical><RegistryNumber>L35JN3I7SJ</RegistryNumber><NameOfSubstance UI="D017257">Ramipril</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017311" MajorTopicYN="N">Amlodipine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017257" MajorTopicYN="N">Ramipril</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18840367</ArticleId><ArticleId IdType="doi">10.1016/j.clinthera.2008.09.008</ArticleId><ArticleId IdType="pii">S0149-2918(08)00301-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15777109</PMID><DateCompleted><Year>2005</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1174-5878</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2005</Year></PubDate></JournalIssue><Title>Paediatric drugs</Title><ISOAbbreviation>Paediatr Drugs</ISOAbbreviation></Journal><ArticleTitle>Pharmacologic treatment of chronic pediatric hypertension.</ArticleTitle><Pagination><StartPage>27</StartPage><EndPage>40</EndPage><MedlinePgn>27-40</MedlinePgn></Pagination><Abstract><AbstractText>Improved recognition of the relationship between childhood and adult blood pressures and identification of end-organ damage in children, adolescents, and young adults with hypertension has led to increased focus by pediatricians and general practitioners on the detection, evaluation, and treatment of hypertension. Notably, detection, evaluation, and treatment of pediatric hypertension has increased significantly since the first Task Force Report on High Blood Pressure in Children and Adolescents in 1977 with advances in both nonpharmacologic and pharmacologic treatments.Angiotensin-converting enzyme inhibitors (e.g. captopril, enalapril, lisinopril, ramipril) and calcium channel antagonists (e.g. nifedipine, amlodipine, felodipine, isradipine) are the most commonly prescribed antihypertensive medications in children due to their low adverse-effect profiles. Diuretics (e.g. thiazide diuretics, loop diuretics, and potassium-sparing diuretics) are usually reserved as adjunct therapy. Newer agents, such as angiotensin receptor antagonists (e.g. irbesartan), are currently being studied in children and adolescents. These agents may be an option in children with chronic cough secondary to angiotensin-converting enzyme inhibitors. beta-Adrenoreceptor antagonists (e.g. propranolol, atenolol, metoprolol, and labetalol), alpha-adrenoreceptor antagonists, alpha-adrenoreceptor agonists, direct vasodilators, peripheral adrenoreceptor neuron agonists, and combination products are less commonly used in pediatric patients because of adverse events but may be an option in children unresponsive to calcium channel blockers, angiotensin converting-enzyme inhibitors, or angiotensin receptor blockers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Renee F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, The Ohio State University College of Medicine and Public Health, Columbus, OH 43205, USA. RobinsonR@pediatrics.ohio-state.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nahata</LastName><ForeName>Milap C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Batisky</LastName><ForeName>Donald L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Mahan</LastName><ForeName>John D</ForeName><Initials>JD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Paediatr Drugs</MedlineTA><NlmUniqueID>100883685</NlmUniqueID><ISSNLinking>1174-5878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000319" MajorTopicYN="N">Adrenergic beta-Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>141</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15777109</ArticleId><ArticleId IdType="doi">10.2165/00148581-200507010-00003</ArticleId><ArticleId IdType="pii">713</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pediatr Cardiol. 1990 Oct;11(4):199-207</Citation><ArticleIdList><ArticleId IdType="pubmed">2274447</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 1997 Nov 24;157(21):2489-94</Citation><ArticleIdList><ArticleId IdType="pubmed">9385301</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1988 May;127(5):946-54</Citation><ArticleIdList><ArticleId IdType="pubmed">3358415</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Hypertens A. 1986;8(4-5):841-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2875815</ArticleId></ArticleIdList></Reference><Reference><Citation>J Behav Med. 1983 Jun;6(2):169-87</Citation><ArticleIdList><ArticleId IdType="pubmed">6352951</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2001 Aug 16;345(7):479-86</Citation><ArticleIdList><ArticleId IdType="pubmed">11519501</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1996 Dec 26;335(26):1968-73</Citation><ArticleIdList><ArticleId IdType="pubmed">8960478</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Dis Child. 1983 Dec;137(12):1162-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6637932</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Nephrol. 1987 Jan;1(1):30-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3153257</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 1987 Jan;79(1):1-25</Citation><ArticleIdList><ArticleId IdType="pubmed">3797155</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1988 Jan 21;318(3):140-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3336401</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 1982 Nov;101(5):777-81</Citation><ArticleIdList><ArticleId IdType="pubmed">7131159</ArticleId></ArticleIdList></Reference><Reference><Citation>Hypertension. 1981 Nov-Dec;3(6):669-75</Citation><ArticleIdList><ArticleId IdType="pubmed">6457796</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 1997 May;50(5):571-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9180649</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Soc Nephrol. 1991 Aug;2(2 Suppl 1):S37-44</Citation><ArticleIdList><ArticleId IdType="pubmed">1932642</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Transplant. 1999 Nov;3(4):288-92</Citation><ArticleIdList><ArticleId IdType="pubmed">10562973</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiovasc Pharmacol. 1988;12 Suppl 7:S94-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2467139</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 1983 Nov;103(5):799-805</Citation><ArticleIdList><ArticleId IdType="pubmed">6355421</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 1991 Jun;118(6):842-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2040918</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hypertens. 1994 Apr;12(4):491-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8064175</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 1989 Oct;84(4):633-41</Citation><ArticleIdList><ArticleId IdType="pubmed">2780125</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hum Hypertens. 1994 May;8(5):389-94</Citation><ArticleIdList><ArticleId IdType="pubmed">8064788</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Pharm Assoc (Wash). 2002 Jan-Feb;42(1):114-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11833502</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hum Hypertens. 1997 Jun;11(6):351-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9249228</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 1988 Apr;112(4):653-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3351693</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust Paediatr J. 1974 Oct;10(5):296-300</Citation><ArticleIdList><ArticleId IdType="pubmed">4447520</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Pharmacol. 2001 Oct;41(10):1064-74</Citation><ArticleIdList><ArticleId IdType="pubmed">11583474</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hum Hypertens. 2001 Mar;15(3):197-201</Citation><ArticleIdList><ArticleId IdType="pubmed">11317205</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hypertens. 2000 Oct;13(10):1061-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11041159</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Pharmacother. 1997 Jun;31(6):704-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9184708</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hum Hypertens. 2001 Jun;15(6):419-23</Citation><ArticleIdList><ArticleId IdType="pubmed">11439318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 1991 Apr;118(4 Pt 1):638-43</Citation><ArticleIdList><ArticleId IdType="pubmed">2007942</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Drug Monit. 1991 Nov;13(6):490-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1837629</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Ann. 1982 Jul;11(7):614-6, 620-1</Citation><ArticleIdList><ArticleId IdType="pubmed">6810289</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 1986;21 Suppl 2:109S-121S</Citation><ArticleIdList><ArticleId IdType="pubmed">3530295</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 1988 Jul;82(1):16-23</Citation><ArticleIdList><ArticleId IdType="pubmed">3288957</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Pharmacol. 1996;50(1-2):147-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8739826</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hypertens Suppl. 1994;12(7):S33-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7769502</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 1992 Jan;120(1):140-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1731011</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Paediatr. 1995 Dec;84(12):1426-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8645963</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Fail. 2000 Jan;22(1):17-26</Citation><ArticleIdList><ArticleId IdType="pubmed">10718277</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1983 Jan;98(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6216842</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Fail. 1987;10(1):9-20</Citation><ArticleIdList><ArticleId IdType="pubmed">3547511</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1997 Nov 15;350(9089):1446-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9371172</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Kidney Dis. 1996 Mar;27(3):305-15</Citation><ArticleIdList><ArticleId IdType="pubmed">8604697</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 1994 Oct;90(4):2166-79</Citation><ArticleIdList><ArticleId IdType="pubmed">7923708</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 1994 Oct;94(4 Pt 1):465-70</Citation><ArticleIdList><ArticleId IdType="pubmed">7936854</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiovasc Pharmacol. 1988;12 Suppl 7:S103-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2467116</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Dis Child. 1983 Mar;137(3):263-6</Citation><ArticleIdList><ArticleId IdType="pubmed">6337472</ArticleId></ArticleIdList></Reference><Reference><Citation>Angiology. 1975 Jan;26(1 Pt. 1):1-14</Citation><ArticleIdList><ArticleId IdType="pubmed">1122043</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 1996 Aug 15;94(4):857-62</Citation><ArticleIdList><ArticleId IdType="pubmed">8772712</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med. 1995 Nov;99(5):497-504</Citation><ArticleIdList><ArticleId IdType="pubmed">7485207</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 1980 Jul;97(1):139-43</Citation><ArticleIdList><ArticleId IdType="pubmed">7381633</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 1977 Sep-Oct;2(5):317-29</Citation><ArticleIdList><ArticleId IdType="pubmed">913002</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hum Hypertens. 2001 Jun;15(6):387-91</Citation><ArticleIdList><ArticleId IdType="pubmed">11439313</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 1979 Aug;64(2):180-6</Citation><ArticleIdList><ArticleId IdType="pubmed">382081</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hypertens. 1995 Nov;8(11):1083-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8554731</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Pharmacol. 1995 May;35(5):484-92</Citation><ArticleIdList><ArticleId IdType="pubmed">7657848</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Heart J. 1989 Nov;118(5 Pt 2):1100-3</Citation><ArticleIdList><ArticleId IdType="pubmed">2530866</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Pharmacol. 1979 Jan;19(1):8-14</Citation><ArticleIdList><ArticleId IdType="pubmed">368088</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiovasc Pharmacol. 1987;10 Suppl 7:S154-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2485054</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Nephrol. 2000 Dec;15(3-4):302-16</Citation><ArticleIdList><ArticleId IdType="pubmed">11149130</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 1976 May;19(5 Pt 1):531-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1277708</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs. 1983 Apr;25(4):339-84</Citation><ArticleIdList><ArticleId IdType="pubmed">6303744</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 1989 Jan;83(1):47-52</Citation><ArticleIdList><ArticleId IdType="pubmed">2642619</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 1987 Sep;111(3):397-400</Citation><ArticleIdList><ArticleId IdType="pubmed">3625408</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1992 May 15;135(10):1166-77</Citation><ArticleIdList><ArticleId IdType="pubmed">1632426</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs. 1996 Jul;52(1):1-16</Citation><ArticleIdList><ArticleId IdType="pubmed">8799681</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Soc Nephrol. 1993 Mar;3(9):1575-82</Citation><ArticleIdList><ArticleId IdType="pubmed">8507813</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 1986 May;21(5):489-95</Citation><ArticleIdList><ArticleId IdType="pubmed">3013265</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Pharmacol (New York). 1982;2(1):49-55</Citation><ArticleIdList><ArticleId IdType="pubmed">7110756</ArticleId></ArticleIdList></Reference><Reference><Citation>Biopharm Drug Dispos. 2000 Dec;21(9):339-44</Citation><ArticleIdList><ArticleId IdType="pubmed">11523062</ArticleId></ArticleIdList></Reference><Reference><Citation>Br Med J (Clin Res Ed). 1983 Feb 19;286(6365):648</Citation><ArticleIdList><ArticleId IdType="pubmed">6297660</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Hypertens A. 1986;8(4-5):847-51</Citation><ArticleIdList><ArticleId IdType="pubmed">3530558</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Nephrol. 1999 May;13(4):304-10</Citation><ArticleIdList><ArticleId IdType="pubmed">10454779</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1989 Aug 31;321(9):580-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2668763</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Nutr. 1989 Dec;8(6):495-503</Citation><ArticleIdList><ArticleId IdType="pubmed">2695549</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hum Hypertens. 2000 Jun;14(6):347-54</Citation><ArticleIdList><ArticleId IdType="pubmed">10878692</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hosp Pharm. 1994 Oct 1;51(19):2409-11</Citation><ArticleIdList><ArticleId IdType="pubmed">7847406</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Pharmacol. 1983 Apr;23(4):161-70</Citation><ArticleIdList><ArticleId IdType="pubmed">6863580</ArticleId></ArticleIdList></Reference><Reference><Citation>Hypertension. 1998 Jan;31(1 Pt 2):546-51</Citation><ArticleIdList><ArticleId IdType="pubmed">9453360</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hypertens. 1991 Feb;9(2):181-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1849536</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Nephrol. 1997 Nov;48(5):307-10</Citation><ArticleIdList><ArticleId IdType="pubmed">9403215</ArticleId></ArticleIdList></Reference><Reference><Citation>Postgrad Med J. 1984 Feb;60(700):132-4</Citation><ArticleIdList><ArticleId IdType="pubmed">6369287</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Pharmacol. 2002 Aug;42(8):870-80</Citation><ArticleIdList><ArticleId IdType="pubmed">12162469</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 1985 Jun;75(6):1091-100</Citation><ArticleIdList><ArticleId IdType="pubmed">3889818</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Int. 1997 Nov;52(5):1169-79</Citation><ArticleIdList><ArticleId IdType="pubmed">9350640</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiovasc Pharmacol. 1992;19 Suppl 5:S21-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1381791</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pediatr. 1998 Aug;157(8):618-21</Citation><ArticleIdList><ArticleId IdType="pubmed">9727842</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiovasc Pharmacol. 1988;12 Suppl 8:S109-15</Citation><ArticleIdList><ArticleId IdType="pubmed">2469891</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 1986 Jan;39(1):43-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3510795</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 1993 Feb;122(2):231-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8429436</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hypertens. 1998 Apr;11(4 Pt 1):418-24</Citation><ArticleIdList><ArticleId IdType="pubmed">9607379</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Dis Child. 1990 Sep;144(9):967-72</Citation><ArticleIdList><ArticleId IdType="pubmed">2396627</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hypertens. 1995 Dec;13(12 Pt 2):1847-51</Citation><ArticleIdList><ArticleId IdType="pubmed">8903665</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 1988 Aug;113(2):403-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3294363</ArticleId></ArticleIdList></Reference><Reference><Citation>Hypertension. 1992 Dec;20(6):834-40</Citation><ArticleIdList><ArticleId IdType="pubmed">1452300</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharm. 1991 Jul;10(7):500-1</Citation><ArticleIdList><ArticleId IdType="pubmed">1860299</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Hypertens A. 1986;8(4-5):871-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3530561</ArticleId></ArticleIdList></Reference><Reference><Citation>J Lab Clin Med. 1989 Sep;114(3):215-21</Citation><ArticleIdList><ArticleId IdType="pubmed">2671214</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiol Clin. 1987 Nov;5(4):629-49</Citation><ArticleIdList><ArticleId IdType="pubmed">2900069</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hypertens. 1991 Feb;9(2):109-14</Citation><ArticleIdList><ArticleId IdType="pubmed">1849524</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 1988 May;112(5):805-10</Citation><ArticleIdList><ArticleId IdType="pubmed">3283314</ArticleId></ArticleIdList></Reference><Reference><Citation>Hypertension. 1981 Nov-Dec;3(6):664-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6457795</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chronic Dis. 1978;31(8):529-37</Citation><ArticleIdList><ArticleId IdType="pubmed">711845</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Nephrol. 2000 Oct;14(12):1083-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11045391</ArticleId></ArticleIdList></Reference><Reference><Citation>J Assoc Physicians India. 1999 Feb;47(2):180-2</Citation><ArticleIdList><ArticleId IdType="pubmed">10999084</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hypertens. 1995 Jul;8(7):657-65</Citation><ArticleIdList><ArticleId IdType="pubmed">7546488</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Int Suppl. 1998 Dec;68:S120-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9839295</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hypertens. 1991 Jul;9(7):639-44</Citation><ArticleIdList><ArticleId IdType="pubmed">1653800</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Dis Child. 1995 Aug;73(2):154-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7574861</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 1990 Oct;82(4):1243-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2401062</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Hypertens A. 1986;8(4-5):829-39</Citation><ArticleIdList><ArticleId IdType="pubmed">3530557</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pediatr (Phila). 1998 Jan;37(1):31-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9475697</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hypertens. 1998 Apr;11(4 Pt 1):497-501</Citation><ArticleIdList><ArticleId IdType="pubmed">9607390</ArticleId></ArticleIdList></Reference><Reference><Citation>Postgrad Med. 1975 Nov;Spec No:9-17</Citation><ArticleIdList><ArticleId IdType="pubmed">172877</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Pharm Assoc (Wash). 1999 May-Jun;39(3):375-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10363465</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Paediatr. 1992 Feb;81(2):145-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1515758</ArticleId></ArticleIdList></Reference><Reference><Citation>J Int Med Res. 1982;10(6):451-4</Citation><ArticleIdList><ArticleId IdType="pubmed">6759197</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Nephrol. 2002 Sep;17(9):748-53</Citation><ArticleIdList><ArticleId IdType="pubmed">12215829</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 1983 Sep;103(3):481-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6886918</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood Press Monit. 2000 Aug;5(4):211-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11035862</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 1977 Jun;21(6):715-20</Citation><ArticleIdList><ArticleId IdType="pubmed">862310</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Pharmacol. 2001 Jul;41(7):742-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11452706</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Rev. 1993 May;14(5):169-79</Citation><ArticleIdList><ArticleId IdType="pubmed">8493186</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Nephrol. 2002 May;17(5):345-50</Citation><ArticleIdList><ArticleId IdType="pubmed">12042891</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pediatr. 1980 Dec;135(2):161-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7004877</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Drug Monit. 1995 Feb;17(1):60-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7725379</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Nephrol. 2000 Nov;15(1-2):113-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11095026</ArticleId></ArticleIdList></Reference><Reference><Citation>South Med J. 2000 Mar;93(3):287-93</Citation><ArticleIdList><ArticleId IdType="pubmed">10728516</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Nutr. 1997 Feb;65(2 Suppl):618S-621S</Citation><ArticleIdList><ArticleId IdType="pubmed">9022557</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hum Hypertens. 1993 Feb;7(1):7-12</Citation><ArticleIdList><ArticleId IdType="pubmed">8450524</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Dis Child. 1978 Jul;53(7):594-6</Citation><ArticleIdList><ArticleId IdType="pubmed">686799</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
